D
DotLab
Healthcare technology company that helps physicians and patients address challenges faced by women with endometriosis
About DotLab
DotLab operates in the healthcare sector, focusing on providing innovative diagnostic solutions for endometriosis, a complex and often misdiagnosed disease affecting millions of women globally. The company's flagship product, DotEndo, is a non-invasive test that measures disease-specific biomarkers and applies advanced biostatistics to provide accurate diagnoses. This test aims to fill a diagnostic gap that has persisted for over a century, offering a much-needed solution for women who have been on a prolonged diagnostic journey. DotLab primarily serves healthcare providers and women suffering from endometriosis, providing them with actionable insights to better manage the disease. The business model revolves around selling the DotEndo test to healthcare institutions and directly to consumers, generating revenue through test sales and potentially through partnerships with healthcare organizations. By addressing a significant unmet need in women's health, DotLab positions itself as a leader in the diagnostic space for endometriosis.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Sacramento, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 75.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Biotechnology, Biomarkers, Surgery, Women's Health, Chronic Disease, Non-Invasive medical devices and treatments, Health Diagnostics, Spinout, Femtech, Sustainable Development Goals
- Technology
- Deep Tech
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning DotLab.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2024 | $250K | $50M | Morgan Stanley | ↗ |
| SERIES A✓Equity / VC | Jul 2019 | $10M | $40M | Luxor Capital · CooperSurgical · Tiger Global | — |
Growth signals
Latest recorded traffic for DotLab is 2.9K monthly website visits, up 0% over the last three months. DotLab's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
CooperSurgical
Luxor Capital
Tiger Global
Morgan Stanley
Other known investors8 additional known investors
Yale University
Yale University School of Medicine
Berkeley SkyDeck Accelerator
G4A
Morgan Stanley Inclusive Ventures Lab
Nucleate
Small Business Innovation Research
Yale Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DotLab on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DotLab’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.